Tenecteplase, sold under the brand name Metalyse among others, is an enzyme used as a thrombolytic drug.[1]
Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using an established mammalian cell line (Chinese hamster ovary cells).[1] Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain.[1]
Tenecteplase was approved for medical use in the United States in June 2000.[1][3]